THE INSTITUTE@PRECISION ASIA-PACIFIC SERIES

The APAC Imperative for Phase III Trials

The question isn’t whether to run your Phase III trial in APAC. It’s how. And how soon. With faster recruitment, access to critical patient populations and the world's second and fourth largest pharmaceutical markets, APAC has become essential to global trial success. Realizing its advantages depends on decisions made long before enrollment begins.

Jump to Form

In this whitepaper, you’ll learn:

How early planning can maximize APAC’s value before Phase III
How country selection influences development, registration and commercialization
What regulatory, operational and cultural realities sponsors should anticipate
Why in-region expertise drives successful trial execution across APAC

Authors:
James Cheong, JingPing Yeo, Zhenfei Yin, Sean Hart

The benefits are obvious. The challenges aren’t.

Access isn’t automatic. Regulatory complexity, site selection and local execution all matter, and most of it gets decided before the trial starts.

Multiple Markets Take Multiple Strategies

Every APAC country has its own regulatory approach, its own recruitment dynamics, its own commercial case. A strategy built around one doesn't automatically apply to the rest.

Plan for Phase III at the Start

Build APAC into the program at Phase I or II, and its regulatory and operational requirements work in your favor. Wait until Phase III, and they slow you down.

Finding the people who find the patients

The best investigators in China are oversubscribed, and they don’t respond to cold outreach. Success depends on established local relationships and knowing how to engage effectively.

FAQs

Why is China's Phase III recruitment 2 to 3x faster?

Large patient populations, high-catchment hospital centers with up to 3,000 to 4,000 beds and reimbursement dynamics that incentivize participation.

Isn’t APAC lower-quality than the US or EU?

No. FDA and EMA inspection findings at APAC sites are comparable in number and nature to inspection findings at US and European sites. China and Japan are also ICH members, following the same clinical trial guidelines as the US and Europe.

If we enroll heavily in one APAC country, will regulators accept the data?

It depends on balance. Overenrolling in a single country can skew a trial's ethnic composition and raise concerns during Western regulatory review. The strongest strategies combine multiple countries deliberately.

The APAC Imperative for Phase III Trials

The benefits are obvious. The challenges aren’t.

FAQs

Explore the APAC Phase III strategies that define success.